newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

  • IGC Pharma announced advances in MINT-AD, an AI-driven initiative leveraging Health and Retirement Study data to identify socioeconomic risk factors for Alzheimer's.
  • The project utilizes 14 large-scale longitudinal aging studies from the USA, Africa, Mexico, China, Costa Rica, Puerto Rico, Chile, Brazil, England, Thailand, Indonesia, India, & Korea.
  • CEO Ram Mukunda stated the AI models aim to reveal hidden relationships between socioeconomic factors & cognitive health to enable personalized non-pharmacological interventions.
  • The initiative is structured around three core objectives: risk stratification for targeted prevention, early detection of cognitive decline using historical data, & modeling disease progression under different interventions.
  • IGC Pharma's AI models seek to address the limitations of current one-size-fits-all treatments by predicting cognitive decline years in advance & modeling various intervention scenarios.
  • The company's lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia.
  • IGC Pharma holds over 30 patent filings with 12 patents granted & maintains a pipeline including TGR-63 & programs targeting neurodegeneration, tau proteins, & metabolic dysfunctions.
  • The press release includes forward-looking statements regarding risks such as regulatory approval, AI algorithm accuracy, & general economic conditions.